At a glance
ClinicalIndex Comparison RecordN/ACompleted· 31 enrolled
Drug / intervention
DiaGone™device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
DiaGone™ First in Human (FIH) Study - Safety and Performance of the DiaGone™ Device for the Treatment of Type 2 Diabetes
In Brief
A clinical study evaluating DiaGone™ for Diabetes Mellitus, Type 2. Completed, enrolled 31 participants across 3 sites in 2 countries.
Detailed Summary
This is a multi-center, prospective, open label study of the Duodenal Glycemic Control™ procedure on type 2 diabetes patients sub-optimally controlled, to examine the safety and initial performance of the DiaGone™ system.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesCzechia, Israel
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartJul 2017
First PostedJan 2018
Primary CompletionAug 2024
TodayJul 2026
First PostedJan 4, 2018
Enrollment StartJul 28, 2017
Primary CompletionAug 31, 2024
TodayJul 2, 2026
Enrollment to primary: 7.1 yearsPosted 8.5 years ago
Interventions
DiaGone™device
Duodenal Glycemic Control™ using the DiaGone™ system